Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty

Next Previous
X
Search
Trial Profile

A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivoligide (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Adynxx

    • Most Recent Events

    • 12 Apr 2018 According to an Adynxx media release, Joseph Gimbel, M.D. (orthopedic surgeon, Chief Medical Director of Arizona Research Center in Phoenix, AZ) is the principal investigator of this study.
    • 12 Apr 2018 According to results presented in an Adynxx media release, in pre-specified analyses by PCS (Pain Catastrophizing Scale) score, brivoligide showed a sustained and clinically meaningful reduction in pain and opioid use in subjects with higher PCS scores.Based on these results, the company plans to initiate a phase 3 clinical trial of brivoligide in subjects with high PCS scores.
    • 12 Apr 2018 Primary endpoint (Mean pain with walking during the 15 meter walk test Day 7 to Day 28) has not been met, according to results presented in an Adynxx media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top